Deals

ArsenalBio reaches next stage of maturity with BMS deal

In first deal with major pharma, ArsenalBio putting synthetic biology toolkit to the test

In its first deal with a major pharma, ArsenalBio will use its synthetic biology toolkit to create programmable T cell therapies against solid tumor targets.

In its first deal with a major pharma, ArsenalBio will put its synthetic biology toolkit to the test in creating programmable T cell therapies against solid tumor targets chosen by BMS.

ArsenalBio as among the first companies to originate from the Parker Institute for Cancer Immunotherapy